An Audience With

Filter By:

Article Type
Year

  • John Jenkins, former Director of the FDA's Office of New Drugs, discusses approvals standards, breakthrough therapy designation and regulatory science hurdles.

    An Audience With

  • John Lechleiter, the retiring Chief Executive Officer at Eli Lilly, discusses his path from the chemistry lab to the executive suite.

    An Audience With

  • Carole Ho, Chief Medical Officer at Denali Therapeutics, discusses how genetic findings have paved the way for one of the largest start-ups to take on neurodegeneration.

    An Audience With

  • Deborah Zarin, director ofClinicalTrials.gov, discusses the new trial registration rules and the need for transparency in the clinical research enterprise.

    An Audience With

  • Michael Rosenblatt, newly appointed Chief Medical Officer of Flagship Ventures and former Chief Medical Officer at Merck & Co., discusses his move from industry to venture capital.

    An Audience With

  • Melissa Paoloni, an architect of the I-SPY 2 trial at QuantumLeap Healthcare Collaborative, discusses the evolution of one of the first adaptive, umbrella trials.

    An Audience With

  • Jim O'Neill, chair of the United Kingdom's review into antimicrobial resistance, says industry needs to up its game in the battle against antimicrobial resistance.

    An Audience With

  • Philip Tetlock, author of Superforecasting, discusses how the pharmaceutical industry can make better predictions.

    An Audience With

  • Alan Shuldiner, co-head of the Regeneron Genetics Center, says that the time for genomic drug discovery has arrived.

    An Audience With

  • Stevin Zorn, executive scientist in residence at Lundbeck Research USA, discusses the growing interest in how inflammation might drive Alzheimer disease and mood disorders.

    An Audience With

  • Arthur Caplan, a medical ethicist at the New York University School of Medicine, discusses how to fairly distribute experimental drugs outside of clinical trials.

    An Audience With

  • Ian Tomlinson, former head of business development for GlaxoSmithKline and now chairman of the Apollo Therapeutics Fund, discusses a new model of pharmaceutical–academic partnership.

    An Audience With

  • Michael Hanson, president of the GPCR Consortium, discusses how industry and academic partners are shedding light on one of the most important classes of drug targets.

    An Audience With

  • Vas Narasimhan, global head of development at Novartis, discusses his plans to increase the efficiency and reduce the cost of trial execution.

    An Audience With

  • Karen Midthun, outgoing Director of the FDA's Center for Biologics Evaluation and Research, reflects on 22 years at the agency.

    An Audience With

  • Husseini Manji, the Global Therapeutic Area Head of Neuroscience at Janssen, discusses the promise of NMDA receptor antagonists, anti-inflammatories and endocannabinoid modulators in psychiatry.

    An Audience With

  • Francis Cuss, Chief Scientific Officer of Bristol-Myers Squibb, discusses immuno-oncology, fibrosis and genetically defined diseases.

    An Audience With

  • Gloria Maldonado, Executive Director of Pfizer's Center of Excellence in Precision Medicine in Chile, discusses pharma's R&D expansion into Latin America.

    An Audience With

  • Pierre Meulien, soon to be the new Executive Director of The Innovative Medicines Initiative, discusses his plans to move the European public-private partnership forward.

    An Audience With

  • Moncef Slaoui, Chairman of Vaccines at GlaxoSmithKline, discusses the GSK–Novartis asset swap, the future of vaccines at GSK, and the implications for the company's remaining oncology programmes.

    An Audience With